Seebri Neohaler FDA Approval History
Last updated by Judith Stewart, BPharm on May 3, 2020.
FDA Approved: Yes (Discontinued) (First approved October 29, 2015)
Brand name: Seebri Neohaler
Generic name: glycopyrrolate
Dosage form: Inhalation Powder
Company: Novartis Pharmaceuticals Corporation
Treatment for: COPD
Seebri Neohaler (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Development timeline for Seebri Neohaler
| Date | Article |
|---|---|
| Oct 29, 2015 | Approval FDA Approves Seebri Neohaler (glycopyrrolate) for COPD |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
